A Phase 1/2 interventional study of MR-146 in Neurotrophic Keratopathy, sponsored by Viatris Inc.. Recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Viatris Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to evaluate the safety, tolerability, and biologically effective dose (BED) of MR-146 for the treatment of Stage 1 and Stage 2 Neurotrophic Keratopathy (NK)
Viatris Inc. is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive a single low dose of MR-146 administered via an intralacrimal gland injection
Genetic: MR-146
participants will receive a single mid-level dose of MR-146 administered via an intralacrimal gland injection
Genetic: MR-146
participants will receive a single high dose of MR-146 administered via an intralacrimal gland injection
Genetic: MR-146
gene therapy product for the treatment of stage I/II NK.
Incidence of Dose-Limiting Toxicities (Safety)
To evaluate the safety of MR-146 through the incidence of Dose-Limiting Toxicities (DLTs)
Time frame: Week 52
Incidence of serious adverse events (Safety)
To evaluate the safety of MR-146 through the incidence of serious adverse events.
Time frame: Week 52
Incidence of adverse events (Safety)
To evaluate the safety of MR-146 through the incidence of adverse events.
Time frame: Week 52
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.